Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...3839404142434445464748...170171»
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Clinical, Journal:  Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors. (Pubmed Central) -  Jul 8, 2022   
    When measuring the levels of PS activity in patients undergoing DOACs, the principles of each reagent should be understood. Furthermore, plasma samples must be collected at the time when plasma concentrations of DOACs are lowest or the DOAC-Stop reagent should be used.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Emergency Department Diagnosis of Postprocedural Hemorrhagic Cholecystitis Utilizing Point-of-Care Ultrasoun. (Pubmed Central) -  Jul 8, 2022   
    A 64-year-old man with a past medical history of paroxysmal atrial fibrillation status post ablation on rivaroxaban, myelodysplastic syndrome, nonalcoholic steatohepatitis, gastroesophageal reflux disease, clonal cytopenias of undetermined significance, hypertension, and chronic pain presented to the ED with complaints of right upper quadrant pain in the setting of a recent transjugular liver biopsy...WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Hemorrhagic cholecystitis is a rare pathology that can be easily recognized during point-of-care ultrasound examination. This allows for rapid diagnosis and surgical consultation to provide the patient with timely definitive management.
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg., warfarin / Generic mfg.
    Clinical, Journal:  Stroke and Thromboembolism in Patients with Heart Failure and Sinus Rhythm: A Matter of Risk Stratification? (Pubmed Central) -  Jul 8, 2022   
    A recent RCT assessed the efficacy of the direct oral anticoagulant rivaroxaban versus placebo in patients with HFrEF (including mildly reduced ejection fraction), SR, and coronary artery disease...There is also an unmet need for evidence around anticoagulation in HF with preserved ejection fraction (HFpEF) and SR. This review explores the current evidence around anticoagulation in patients with HF and SR, identifies challenges regarding outcome definitions and patient selection, and offers suggestions for future research.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo, Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Review, Journal:  Methods to Correct Drug-Induced Coagulopathy in Bleeding Emergencies: A Comparative Review. (Pubmed Central) -  Jul 8, 2022   
    This review article also covers laboratory testing and is meant as a guide for physicians on best practices. These findings illustrate recommended testing and reversal techniques based off evidence-based medicine and literature.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Clinical guideline, Review, Journal:  2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. (Pubmed Central) -  Jul 8, 2022   
    The 2022 clinical practice guidelines, which are based on a literature review up to Jan 1, 2022, include guidance for patients with cancer and with COVID-19. Key recommendations (grade 1A or 1B) include: (1) low-molecular-weight heparins (LMWHs) for the initial (first 10 days) treatment and maintenance treatment of cancer-associated thrombosis; (2) direct oral anticoagulants for the initial treatment and maintenance treatment of cancer-associated thrombosis in patients who are not at high risk of gastrointestinal or genitourinary bleeding, in the absence of strong drug-drug interactions or of gastrointestinal absorption impairment; (3) LMWHs or direct oral anticoagulants for a minimum of 6 months to treat cancer-associated thrombosis; (4) extended prophylaxis (4 weeks) with LMWHs to prevent postoperative venous thromboembolism after major abdominopelvic surgery in patients not at high risk of bleeding; and (5) primary prophylaxis of venous thromboembolism with LMWHs or direct oral anticoagulants (rivaroxaban or apixaban) in ambulatory patients with locally advanced or metastatic pancreatic cancer who are treated with anticancer therapy and have a low risk of bleeding.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Review, Journal:  Adrenal hemorrhage following direct oral anticoagulant (DOAC) therapy: two case reports and literature review. (Pubmed Central) -  Jul 7, 2022   
    Given the history of our cases, physicians should be aware of AH in patients receiving DOACs, particularly in elderly patients who are at high risk of bleeding. It is also worth noting that AH can occur in any patient with any medical history and history of DOAC use, which is why patients must be closely monitored.
  • ||||||||||  rivaroxaban / Generic mfg.
    Surgical Management of a Large Primary External Iliac Vein Aneurysm () -  Jul 6, 2022 - Abstract #VAM2022VAM_877;    
    On post-operative day two the catheter was removed, and the patient was started on Xarelto 15mg BID with a plan to transition to 20mg daily... There is a role for open repair of large iliac vein aneurysms using prosthetic interposition graft in combination with long-term anticoagulation.
  • ||||||||||  rivaroxaban / Generic mfg., clopidogrel / Generic mfg.
    Factor Xa Inhibitor in Peripheral Revascularization: A Vascular Quality Initiative Analysis () -  Jul 6, 2022 - Abstract #VAM2022VAM_823;    
    Addition of a FXI correlated with decreased overall all-cause mortality and rates of major amputation but also with increased rates of target vessel/lesion reintervention and ALI in a large, multinational database. Further analysis is needed to investigate the real-world application of FXI in peripheral revascularization.
  • ||||||||||  Post COVID-19 Arterial Thrombosis: A Systematic Review () -  Jul 6, 2022 - Abstract #VAM2022VAM_771;    
    Microcirculatory alterations can be reflected in a panel of biomarkers. The medical and surgical management of these patients may depend on the availability of resources regarding the context of medical attention.
  • ||||||||||  rivaroxaban / Generic mfg., fondaparinux / Generic mfg.
    Periprocedural Thromboprophylaxis for Superficial Venous Interventions: Literature Review () -  Jul 6, 2022 - Abstract #VAM2022VAM_763;    
    There is significant variability in the type of drug, duration of treatment, and selection criteria. The heterogeneity of periprocedural thromboprophylaxis in superficial venous interventions emphasizes the need for a large multi-center randomized clinical trial to provide standardized evidence-based guidelines.